Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
3
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
abbvie
alzheimer's disease
biotech
boulder/denver blog main
boulder/denver top stories
cystic fibrosis
deals
detroit blog main
detroit top stories
diagnostics
gilead sciences
indiana blog main
indiana top stories
merck
national
novartis
pfizer
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
adverum biotechnologies
albert bourla
What
ceo
3
×
drug
3
×
acquisitions
biggest
bio
roundup
week
aces
albert
announced
big
bourla
build
buy
cholesterol
company
company’s
crispr
daniel
debut
dyne’s
flexible
future
gilead
imports
inclisiran
key
lowering
maker
maps
meant
measured
medco
medicine
medicines
microbiome
moves
nasdaq
open
openly
Language
unset
unknown
Current search:
ceo
×
drug
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More